United States News Todas as matérias

Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.

Beijing-based Global Mofy Metaverse Limited (NASDAQ:GMM), a technology platform specializing in AI-driven virtual content creation for the metaverse and entertainment industries, reported record financial results for its fiscal year ended September 30, 2025.

Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.

Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.

Indianapolis-based Hurco Companies (NASDAQ:HURC), a global provider of computerized machine tools and software, reported financial results for its fiscal year ended October 31, 2025.

Schrödinger (NASDAQ:SGDR) announced a strategic collaboration with Eli Lilly and Company (NYSE:LLY) on Friday to integrate Lilly’s high-powered TuneLab™ AI platform directly into Schrödinger’s flagship enterprise software, LiveDesign.

Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.

Polestar Automotive Holding UK (NASDAQ:PSNY) reported its strongest sales year to date on Friday, defying a broader slowdown in the electric vehicle sector with a 34% surge in annual retail deliveries.

The Kroger Company (NYSE:KR) completed the sale of its online health-and-wellness subsidiary, Vitacost.com, to iHerb on Friday, a move aimed at excising non-core digital assets as the grocery giant narrows its focus on its primary retail operations and high-return business lines.

Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.

Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.

Amarin Corporation (NASDAQ:AMRN) commented on recent therapeutic advances for patients with elevated triglycerides, asserting that its flagship VASCEPA/VAZKEPA (icosapent ethyl) franchise remains strongly positioned to benefit from broader category commercialization efforts.

California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.

Lindsay Corporation (NYSE:LLN), a global heavyweight in automated irrigation systems and roadway infrastructure, announced Friday that its Board of Directors has authorized a regular quarterly cash dividend of $0.37 per share.

Liquidia Corporation (NASDAQ:LQDA) reported preliminary, unaudited commercial performance metrics for its lead product YUTREPIA (treprostinil) inhalation powder for the fourth quarter and full year ended December 31, 2025.

Meta Platforms (NASDAQ:META) said Friday it has signed 20-year power purchase agreements to buy electricity from three Vistra Corp. nuclear plants in the U.S. Midwest and entered development partnerships with two companies pursuing small modular reactor technology, as Big Tech races to lock in reliable, long-term energy supplies for expanding artificial intelligence and data center operations.

Haemonetics Corp. (NYSE:HAE) announced Friday it has acquired Vivasure Medical Limited, a Galway-based pioneer in vessel closure technology, in a move that significantly broadens its reach into the $2.5 billion global vascular closure market.

Kezar Life Sciences (NASDAQ:KZR) announced Friday that the FDA has granted a formal Type C meeting for the first quarter of 2026, a move that could revive the clinical path for its lead asset, zetomipzomib, following months of regulatory uncertainty.

ChipMOS TECHNOLOGIES (NASDAQ:IMOS) reported a sharp rise in fourth-quarter revenue on Friday, as the specialized semiconductor packager benefits from a "perfect storm" of high-density memory demand and a strategic shift toward AI-related infrastructure.

Sanuwave Health (NASDAQ:SNWV) reported preliminary fourth-quarter revenue that reached an all-time high, as the medical device maker effectively navigated a volatile reimbursement landscape that has left many of its competitors in the wound-care sector reeling.

Taiwan Semiconductor Manufacturing Company (NYSE:TSM), the world's largest contract chipmaker, reported fourth-quarter revenue that rose 20.45% from the year-ago period on surging interest in artificial intelligence applications.

Mesoblast (NASDAQ:MESO) reported a breakout quarter for its flagship cellular medicine, Ryoncil, with sales jumping 60% to reach $35.1 million for the period ended December 31, 2025.

AnaptysBio (NASDAQ:ANAB) moved to dismantle a key legal pillar of GSK’s (NYSE:GSK) defense in the Delaware Chancery Court on Thursday, filing a motion to dismiss claims that the biotech "repudiated" its lucrative royalty agreement for the blockbuster-intent cancer drug Jemperli.

Appian Corp. (NASDAQ:APPN) announced it will pursue a second trial in its long-running trade secrets battle against Pegasystems (NASDAQ:PEGA0, following a Virginia Supreme Court ruling that refused to dismiss the case but sent it back to a lower court for a fresh look.